Rubicon Healthcare Partners (RHP) is a Nordic life-science asset manager focused on growth-stage companies that enable the future of medicine. They partner with ambitious teams in the backbone industries of healthcare — from manufacturing technologies to advanced research tools — providing capital, competence, and a collaborative network to accelerate growth. The firm aims to deliver exceptional returns by investing in high-quality, high-growth life science companies — fostering innovation and global expansion of outstanding Nordic businesses, and securing dual returns: economic and societal. RHP targets proven life-science companies positioned for scale — typically post proof-of-concept, with established revenue and strong technology differentiation. They aim to build the bridge between the flourishing Nordic life science sector and global markets, investing as a partner around a framework of integrity, flexibility, and transparency. The firm focuses on companies facilitating the production of advanced therapy products through scalable tools and process innovation, platforms that enhance discovery, quality control, and analytical precision in pharmaceutical R&D and manufacturing, and solutions that modernise diagnostics and the digital infrastructure of biopharma and healthcare systems.
Bevorzugte Reifephase für die erste Finanzierung.
Manufacturing and Enabling Technologies, Research, Development, and Analytical Tools, Healthcare Technology and Services
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Standard-Finanzierungsbetrag pro Runde.
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...